SLU-PP-332 (Exercise Mimetic)

Synthetic Pan-ERR Agonist | Exercise Mimetic & Metabolic Modulator

Weight: 290.32 Da
Half-life: Under investigation (no human PK data)
Chain: Non-peptide small molecule
4 studies
2024 latest
2 recent
Emerging
Dose NO HUMAN DOSE ESTABLISHED (animal studies: 50 mg/kg IP)
Frequency Research only - not approved for human use
Cycle No human protocols established
Storage 2-8°C refrigerated for research use

Community Research

Join others researching SLU-PP-332 — share findings, ask questions, and learn from real experiences

View Results Aggregated community findings
Discussion Questions & experiences
Submit Your Findings Contribute your research data

Groundbreaking synthetic compound from Saint Louis University functioning as pan-estrogen-related receptor agonist with preferential ERRα activity. Activates metabolic pathways engaged during physical exercise without physical activity requirement.

Mechanism of Action

Binds and activates ERRα/β/γ which regulate energy metabolism gene expression. Upregulates PGC-1α (mitochondrial biogenesis master regulator), activates AMPK pathway, increases mitochondrial density to 1.8-fold, enhances oxidative phosphorylation and ATP production.

01 Exercise mimetic effects without physical activity
02 12% weight loss in 28 days
03 70% increased endurance
04 25% enhanced fatty acid oxidation
05 Improved insulin sensitivity
06 Reduced hepatic steatosis
07 Cardiac protection
08 Reversal of age-related mitochondrial dysfunction

Molecular Data

Molecular Weight
290.32 Da
Chain Length
Non-peptide small molecule
Type
Synthetic ERR agonist
Amino Acid Sequence
(E)-4-Hydroxy-N'-(naphthalen-2-ylmethylene)benzohydrazide

Complex or non-standard sequence format

Research Indications

Metabolic Health
Weight Loss & Body Composition most effective

12% body weight reduction in 28 days without appetite suppression. Fat mass gain <0.5g vs ~5g controls.

Insulin Sensitivity & Glucose Control most effective

Significantly improved glucose tolerance in obese mice with lower fasting glucose and insulin levels.

Energy Expenditure Enhancement most effective

Increases resting energy expenditure by 25% for fatty acid oxidation within 2 hours.

Liver Health & NAFLD most effective

Reduced hepatic steatosis, decreased hepatic triglycerides, and enhanced hepatic fatty acid oxidation.

Exercise Performance
Endurance Improvements effective

70% increase in running time and 45% increase in running distance in preclinical models.

Muscle Fiber Remodeling effective

Increased type IIa oxidative skeletal muscle fibers with enhanced oxidative capacity.

Cardiovascular
Cardiac Function Improvement moderate

Improved ejection fraction in heart failure models with reduced cardiac fibrosis.

Anti-Aging
Mitochondrial Aging Reversal moderate

First compound to reverse age-related mitochondrial dysfunction in 21-month-old mice.

Kidney Protection
Age-Related Kidney Disease moderate

Reversed age-related albuminuria increase and prevented podocyte loss in elderly mice.

Dosing Protocols

Research compound - IP injection in animals only. No human administration protocols established.

GoalDoseFrequencyRoute
Standard Metabolic Protocol50 mg/kg (animal dosing)Twice dailyIntraperitoneal injection (IP)
Acute Exercise Enhancement50 mg/kg (animal dosing)Single dose 1 hour pre-exerciseIntraperitoneal injection (IP)
Extended Treatment50 mg/kg (animal dosing)Twice daily for 4-8 weeksIntraperitoneal injection (IP)

Reconstitution Instructions

Materials Needed:
  • Bacteriostatic water (BAC) required
  • Sterile technique essential
  1. 1 WARNING: Not tested in humans - research only
  2. 2 Do NOT use outside approved research protocols
  3. 3 Dosing cannot be extrapolated from animals to humans
  4. 4 No human clinical trials initiated as of 2025
  5. 5 Oral formulation in development
  6. 6 Consult medical professionals before experimental use

Interactions

~
Metformin
Both affect mitochondrial function and AMPK pathways - may have additive metabolic effects. Monitor blood glucose closely.
monitor
~
Insulin
Enhanced insulin sensitivity may require significant dose reduction to prevent hypoglycemia.
monitor
~
Tirzepatide
Different mechanisms affecting weight loss and metabolism - combination could have additive effects.
monitor
~
Semaglutide
Combining GLP-1 and ERR agonism may enhance metabolic effects - monitor weight loss rate closely.
monitor
+
5-Amino-1MQ
Distinct mechanisms (ERR agonism vs NNMT inhibition) likely complementary without known interactions.
compatible
++
NAD+
Complementary mitochondrial pathways - SLU-PP-332 increases biogenesis while NAD+ supports energy production.
synergistic
+
CJC-1295
GH optimization may complement metabolic enhancement for body composition without known interactions.
compatible
+
Ipamorelin
May preserve lean muscle during SLU-PP-332-induced fat loss through GH pathway.
compatible

What to Expect

Hours 1-6
Metabolic shift toward fat oxidation within 2 hours; gene expression changes at 3-6 hours; enhanced exercise performance 1 hour post-dose
Week 1
Increased resting energy expenditure measurable; enhanced fatty acid oxidation by 25%; improved grip strength by day 6
Week 2-4
Up to 12% weight loss by day 28; dramatic fat mass reduction; improved glucose tolerance; 45-70% endurance improvements; reduced hepatic steatosis
Week 6-8
Cardiac improvements (ejection fraction, reduced fibrosis); age-related kidney dysfunction reversal; mitochondrial architecture restoration
Long-term (5+ months)
Sustained anti-aging effects in aging studies; continued tissue mitochondrial improvement; duration after discontinuation unknown

Side Effects & Safety

Common Side Effects

  • Animal studies show favorable safety with no severe effects at therapeutic doses
  • Well-tolerated in rodents and canines
  • No liver, kidney, or cardiac toxicity documented
  • No lean mass loss
  • Does not suppress hormones or act as stimulant
  • Minor plasma cholesterol and liver enzyme changes in some studies

Stop Signs - Discontinue if:

  • Severe hypoglycemia (especially with diabetes medications)
  • Any cardiovascular symptoms (chest pain, palpitations, shortness of breath)
  • Signs of liver dysfunction (jaundice, dark urine, severe abdominal pain)
  • Kidney problems (reduced urination, swelling, severe back pain)
  • Severe headaches or neurological symptoms
  • Allergic reactions (rash, hives, difficulty breathing, swelling)

Contraindications

  • NOT FOR HUMAN USE - no approved human dose
  • No human clinical trials conducted
  • Potential interaction with diabetes medications

Quality Checklist

Good Signs

  • Legitimate research supplier with Certificate of Analysis
  • From reputable chemical suppliers (Cayman Chemical, Sigma-Aldrich)
  • Proper labeling as 'Research Use Only'
  • Batch numbers and purity data (typically >98%)

Warning Signs

  • Research chemical only - NOT FOR HUMAN USE
  • NOT FDA approved - no human clinical trials
  • Available only for legitimate research through licensed suppliers

Bad Signs

  • Any product marketed for human consumption is illegal
  • Unknown purity or contamination without lab testing
  • Lack of proper HPLC or mass spectrometry verification
  • Products without 'Research Use Only' labeling

References

  • A Synthetic ERR Agonist Alleviates Metabolic Syndrome
    Billon C, Schoepke E, Avdagic A, Chatterjee A, Butler AA, Elgendy B, Walker JK, Burris TP
    Journal of Pharmacology and Experimental Therapeutics (2024)

    Diet-induced obese mice, 50 mg/kg IP twice daily, 28 days: 12% body weight loss, 25% fatty acid oxidation increase, improved glucose tolerance, reduced hepatic steatosis. SLU-PP-332 mimics exercise-induced metabolic benefits.

  • Synthetic ERRα/β/γ Agonist Induces an ERRα-Dependent Acute Aerobic Exercise Response and Enhances Exercise Capacity
    Billon C, Sitaula S, Banerjee S, Welch R, Elgendy B, Hegazy L, Oh TG, Kazantzis M, Chatterjee A, Chrivia J et al.
    ACS Chemical Biology (2023)

    Multiple mouse models, 50 mg/kg IP: 70% increase in running time, 45% increase in running distance, increased type IIa oxidative muscle fibers. SLU-PP-332 is a synthetic ERR pan agonist with highest potency for ERRα.

  • Estrogen-Related Receptor Agonism Reverses Mitochondrial Dysfunction and Inflammation in the Aging Kidney
    Wang XX, Myakala K, Libby AE, Krawczyk E, Panov J, Jones BA, Bhasin K, Shults N, Qi Y, Krausz KW et al.
    American Journal of Pathology (2023)

    21-month-old mice, 8-week treatment with SLU-PP-332: Reversed age-related increases in albuminuria, podocyte loss, mitochondrial dysfunction, and inflammatory cytokines.

  • Novel Pan-ERR Agonists Ameliorate Heart Failure Through Enhancing Cardiac Fatty Acid Metabolism and Mitochondrial Function
    Xu W, Billon C, Li H, Wilderman A, Qi L, Graves A, Rideb JRDC, Zhao Y, Hayes M, Yu K et al.
    Circulation (2024)

    Both SLU-PP-332 and SLU-PP-915 significantly improved ejection fraction, ameliorated fibrosis, and increased survival in pressure overload-induced heart failure without affecting cardiac hypertrophy. Transcriptionally activated fatty acid metabolism and mitochondrial function genes.

Related Peptides

5-Amino-1MQ compatible

Distinct mechanisms (ERR agonism vs NNMT inhibition) likely complementary without known interactions.

NAD+ synergistic

Complementary mitochondrial pathways - SLU-PP-332 increases biogenesis while NAD+ supports energy production.

Ipamorelin compatible

May preserve lean muscle during SLU-PP-332-induced fat loss through GH pathway.

Disclaimer

This information is for educational and research purposes only. Consult a healthcare professional before use.